

# VIVORYON THERAPEUTICS AG

ISIN: NL00150002Q7 WKN: - Asset Class: Stock

## Company

2024/05/10 17:35:10



Price

**0.80** EUR

Difference ▼ -1.85% (-0.02)



## Contact Details

VIVORYON THERAPEUTICS NV

Tel: +49-345-555-99-00

--

Fax: +

Weinbergweg 22

Web:

<http://www.vivoryon.com>

06120 Halle

E-mail: [info@vivoryon.com](mailto:info@vivoryon.com)

## Company Profile

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	29,812,000		30,694,000		20,229,000	
<b>Common stock capital</b>		26,067,000		24,105,000		20,050,000
<b>Fixed assets</b>	1,017,000		684,000		4,291,000	
<b>Equity capital of a company</b>		26,282,000		26,506,000		16,557,000
<b>Cash and cash equivalents</b>	18,562,000		26,555,000		14,661,000	
<b>Accrued liabilities</b>		1,365,000		1,335,000		1,835,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		3,182,000		3,265,000		5,051,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,365,000		1,607,000		2,912,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		513,000
<b>Total assets</b>	30,829,000	30,829,000	31,378,000	31,378,000	24,520,000	24,520,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	17	17	17
<b>Equity ratio</b>	85.25%	84.47%	67.52%
<b>Debt-equity ratio</b>	17.30%	18.38%	48.09%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.82%	0.70%	-3.53%

# VIVORYON THERAPEUTICS AG

ISIN: NL00150002Q7 WKN: - Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	-3,620,000	0	10,764,000
<b>Net income</b>	-28,342,000	-28,156,000	-12,655,000
<b>EBIT</b>	-28,998,000	-28,373,000	-12,220,000
<b>Operating income before taxes</b>	-28,576,000	-28,355,000	-12,223,000
<b>Cash Flow</b>	-21,541,000	-21,794,000	-11,257,000
<b>Net interest income</b>	422,000	18,000	-3,000
<b>Research and development expenses</b>	17,637,000	20,224,000	17,452,000
<b>Income taxes</b>	-234,000	-199,000	432,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	-212,941	0	633,176

## Board of Directors

Erich Maximilian Platzer	Chairman of Supervisory Board
Claudia Riedi	Member of Supervisory Board
Michael Schaeffer	Member of Supervisory Board
Samir Shah	Member of Supervisory Board
Anne Doering	Member of Supervisory Board
Charlotte Lohmann	Member of Supervisory Board

## Members of Management Board

Frank Weber	Chairman of Managing Board
Michael Schaeffer	Member of Executive Committee
Anne Doering	Member of Executive Committee
Florian Schmid	Member of Executive Committee